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Background—Mutations in the LCAT gene cause lecithin:cholesterol acyltransferase (LCAT) deficiency, a very rare
metabolic disorder with 2 hypoalphalipoproteinemia syndromes: classic familial LCAT deficiency (Online Mendelian
Inheritance in Man No. 245900), characterized by complete lack of enzyme activity, and fish-eye disease (Online
Mendelian Inheritance in Man No. 136120), with a partially defective enzyme. Theoretically, hypoalphalipoproteinemia
cases with LCAT deficiency should be at increased cardiovascular risk because of high-density lipoprotein deficiency
and defective reverse cholesterol transport.
Methods and Results—The extent of preclinical atherosclerosis was assessed in 40 carriers of LCAT gene mutations from
13 Italian families and 80 healthy controls by measuring carotid intima-media thickness (IMT). The average and
maximum IMT values in the carriers were 0.07 and 0.21 mm smaller than in controls (P0.0003 and P0.0027),
respectively. Moreover, the inheritance of a mutated LCAT genotype had a remarkable gene-dose–dependent effect in
reducing carotid IMT (P0.0003 for average IMT; P0.001 for maximum IMT). Finally, no significant difference in
carotid IMT was found between carriers of LCAT gene mutations that cause total or partial LCAT deficiency (ie, familial
LCAT deficiency or fish-eye disease).
Conclusions—Genetically determined low LCAT activity in Italian families is not associated with enhanced preclinical
atherosclerosis despite low high-density lipoprotein cholesterol levels. This finding challenges the notion that LCAT is
required for effective atheroprotection and suggests that elevating LCAT expression or activity is not a promising
therapeutic strategy to reduce cardiovascular risk. (Circulation. 2009;120:628-635.)
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A number of epidemiological studies have consistentlydemonstrated that a low plasma concentration of high-
density lipoprotein cholesterol (HDL-C) is an independent
risk factor for atherosclerotic vascular disease. Clinical se-
quelae are generally preceded by silent changes in the arterial
wall, characterized by enhanced lipid deposition and infiltra-
tion of blood cells into the subendothelial space, with thick-
ening of the arterial wall before formation of atherosclerotic
plaques. HDL is believed to retard the formation of athero-
sclerotic lesions by removing excess cholesterol from cells1
and by preventing endothelial dysfunction.2 These mecha-
nisms may imply an increased thickening of the arterial wall
and an enhanced formation of atherosclerotic plaques in
individuals with low plasma HDL-C levels.
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Carotid intima-media thickness (IMT) accurately depicts
the distance between blood-intima and media-adventitia in-
terfaces of the carotid wall and is one of the best-established
and most commonly used surrogate markers of atherosclero-
sis.3 It correlates with many cardiovascular risk factors,
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including low plasma HDL-C levels,4,5 and with the severity
of coronary artery disease (CAD).6 More importantly, in
prospective studies, carotid IMT predicts clinical CAD.7
A variety of molecular defects underlie primary hypoal-
phalipoproteinemia (Online Mendelian Inheritance in Man
No. 604091), a group of rare inherited metabolic disorders, all
characterized by extreme reductions of plasma HDL-C levels.
Although the affected subjects should be exposed to acceler-
ated atherosclerosis and enhanced CAD risk, these are not
invariable findings. Paradigmatic is the case of rare mutations
in the APOA-I gene causing hypoalphalipoproteinemia, some
of which lead to enhanced carotid IMT and premature CAD,8
whereas others are associated with perfectly normal carotid
IMT and CAD protection.9
Lecithin:cholesterol acyltransferase (LCAT) is a HDL-
associated enzyme responsible for esterifying free cholesterol
to cholesteryl ester within the plasma compartment.10 Ho-
mozygous mutations in the LCAT gene cause LCAT defi-
ciency, a very rare metabolic disorder with 2 hypoalphali-
poproteinemia syndromes: classic familial LCAT deficiency
(FLD) (Online Mendelian Inheritance in Man No. 245900),
characterized by complete lack of enzyme activity, and
fish-eye disease (FED) (Online Mendelian Inheritance in
Man No. 136120), with a partially defective enzyme.11
Theoretically, hypoalphalipoproteinemia cases with LCAT
deficiency should be at increased CAD risk because of HDL
deficiency and defective reverse cholesterol transport. A
review of scattered reports published until 1997 indicated that
FLD cases generally do not present with premature CAD,
which was instead described in a consistent number of FED
cases.12 However, the essentially anecdotal nature of CAD
prevalence data in LCAT-deficient families leaves the issue
of atherosclerosis and CAD risk in hypoalphalipoproteinemia
with LCAT deficiency still open. We have recently identified
13 Italian families carrying 17 different LCAT gene muta-
tions, the largest series of LCAT-deficient families reported
to date.13 Here we report on the extent of preclinical athero-
sclerosis, as assessed by carotid IMT, in a large group of
homozygous and heterozygous carriers of LCAT gene muta-
tions from these Italian families.
Methods
Subjects
All members of the 13 previously identified LCAT-deficient fami-
lies13 who were older than 18 years were asked to take part in the
present study. Forty-six of the 82 eligible subjects volunteered for
the study; these included 12 carriers of 2 mutant LCAT alleles, 28
carriers of 1 mutant LCAT allele, and 6 unaffected subjects. Because
of the small number of available unaffected family members, a group
of control subjects was recruited among blood donors (BD) attending
the Servizio Immunoematologico Trasfusionale of the Niguarda
Hospital in Milano.9 The BD database includes 7000 subjects; 276
of them could be matched for sex and age (up to 5 years older or
younger than the carriers) to 1 of the carriers of mutant LCAT alleles.
They were all asked to take part in the study if they did not have a
personal history of cardiovascular disease; the first 80 subjects
corresponding to each match who agreed to participate were selected
for comparison (BD controls).
Medical personal and family history of cardiovascular diseases,
presence of cardiovascular risk factors (smoking, hypertension,
diabetes, obesity), and use of medication were surveyed by
questionnaires. Blood pressure, height, and weight were mea-
sured. Hypertension was defined as a blood pressure 140/
90 mm Hg or use of antihypertensive medication. None of the
participating subjects was taking drugs known to affect plasma
lipid/lipoprotein levels. All subjects were fully informed of the
modalities and end points of the study and signed an informed
consent, and the procedures were approved by the institutional
review board.
Carotid Ultrasonography
The 13 LCAT-deficient families are spread all around Italy. All
carriers who agreed to participate in the study were asked to attend
the Lipid Clinic of the Center E. Grossi Paoletti in Milano for IMT
assessment. Twenty-two subjects traveled to Milano. All BD con-
trols attended the same Lipid Clinic. In all of these subjects,
ultrasound scanning of carotid arteries was performed by a single
sonographer, with the use of an ESAOTE TECHNOS machine,
equipped with a multifrequency probe of 8.5 MHz. When carriers
could not travel to Milano, the sonographer moved to the family’s
site. In this case, ultrasound scanning was performed by using a
portable device (Logiq E compact ultrasound portable system; GE),
equipped with a 5.0- to 13.0-MHz linear array transducer. The same
standard protocol, with scanning of the far walls of the right and left
common carotid artery, bifurcation, and internal carotid artery in 3
different projections (anterior, lateral, and posterior), was used with
both instruments.14 Videotape recordings were subsequently exam-
ined by a single expert reader using a specific software (M’Ath,
Metris SRL France) that allows semiautomatic edge detection of the
echogenic lines of the intima-media complex. Both sonographer and
reader were blinded to the subject’s identity. The far wall of the
common carotid artery (in its entire length), the bifurcation, and the
first proximal centimeter of the internal carotid artery were measured
in at least 3 different frames. All measurements were averaged to
calculate the average IMT for each subject; the highest IMT value
among the 3 segments was defined as the maximum IMT. When IMT
measurements obtained with the 2 ultrasound devices were compared by
assessing carotid IMT in 20 subjects with varying degrees of preclinical
atherosclerosis attending the Lipid Clinic,15 little bias was observed
between the 2 devices (common carotid IMT: mean difference
[MD]0.031 mm, limits of agreement [LOA]0.063, 0.001 mm;
bifurcation IMT: MD0.013 mm, LOA0.089, 0.063 mm; inter-
nal carotid IMT: MD0.012 mm, LOA0.060, 0.037 mm; average
IMT: MD0.017 mm, LOA0.036, 0.002 mm; maximum IMT:
MD0.012 mm, LOA0.118, 0.094 mm).
Biochemical Analyses
Fasting blood samples were collected after an overnight fast. Plasma
total cholesterol, HDL-C, triglyceride, and apolipoprotein levels
were determined with certified methods by using a Roche diagnos-
tics Integra 400 autoanalyzer. Plasma lipoproteins were separated by
sequential ultracentrifugation with the use of a Beckman TL 100
ultracentrifuge equipped with a TL 100.3 rotor, and the cholesterol
content of lipoprotein fractions was measured by enzymatic
techniques.
Differential Diagnosis
Differential FLD and FED diagnosis in carriers of 2 mutant LCAT
alleles was based on biochemical criteria.13 Because carriers of 1
mutant LCAT allele cannot be classified as FLD or FED on the basis
of either biochemical or clinical criteria,11 differential genetic diag-
nosis was performed by expressing LCAT mutants, as well as the
wild-type LCAT protein, in COS-1 cells and measuring LCAT
concentration and activity in the cell medium.
LCAT cDNA was cloned into the pSVDNALCAT vector with the
use of a double BamHI site. This plasmid was used as a template to
introduce the mutations by the QuikChange XL mutagenesis kit
(Stratagene). Clones were propagated in XL1Blue bacteria cells and
controlled by direct sequencing. COS-1 cells were grown in high-
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glucose Dulbecco’s modified Eagle’s medium media supplemented
with 5% fetal bovine serum, 2 mmol/L L-glutamine, 100 UI/mL
penicillin, 100 g/mL streptomycin, 1 mmol/L Na-pyruvate, and1
nonessential amino acids. Cells were seeded into 60-mm dishes at a
density of 400 000 cells per dish. Cells were transfected at 60% to
90% of confluence (24 hours after seeding) with Lipofectamine
Reagent (Invitrogen, Carlsbad, Calif) or Lipofectamine 2000 (In-
vitrogen) according to the manufacturer’s instructions. The pSVD-
NALCAT wild-type and mutant vectors were always cotransfected
with pCMV -Gal vector, expressing -Gal gene, to assess the
transfection efficiency. Twenty-four hours after transfection, the
medium of transfected cells was substituted with a cell-free medium
(Optimem, GIBCO) to avoid interference with the LCAT enzyme
present in serum-containing medium. Seventy-two hours after trans-
fection, the medium of transfected cells was collected and centri-
fuged for 10 minutes at 2000g at 4°C to remove cellular debris.
Aliquots of the media were kept at 80°C until LCAT assays were
performed. Plasma LCAT concentration was measured by an immu-
noenzymatic assay.16 LCAT activity was measured with the use of
reconstituted HDL and plasma-derived low-density lipoprotein
(LDL) as substrate.13
Statistical Analyses
Data with near-normal distributions are presented as mean and SD.
IMT variables, which have skewed distributions, were log-
transformed before analysis and are presented as geometric means
and 95% confidence intervals (CIs). Unadjusted comparisons of
demographic and clinical data were performed by 2-sample t test.
Unadjusted IMT values were compared by the Wilcoxon rank sum
test. Comparisons adjusted for potential confounders (age, sex, body
mass index [BMI], smoking status, hypertension, family history of
cardiovascular disease, ultrasound device, and total cholesterol,
HDL-C, and triglyceride levels) were performed by ANCOVA. Two
models were tested to assess the effect of LCAT genotype on IMT
measurements: a dominant model, with LCAT deficiency entered as
a dichotomous variable, and a gene-dose model including the
number of mutant LCAT alleles (0, 1, or 2). All tests were 2-sided,
and P values 0.05 were considered statistically significant. All
analyses were performed by SAS statistical package version 9.13
(SAS Institute Inc, Cary, NC).
Results
Carotid IMT in Carriers and Controls
A total of 120 subjects, 40 carriers of LCAT gene mutations
(carriers) and 80 matched BD controls, participated in the
study (Table 1). As per protocol, age was comparable in the
2 study groups; BMI, blood glucose, and smoking status were
also similar. Three carriers and 8 controls had prediabetes,
and 1 carrier had type 2 diabetes mellitus. Because of the
inclusion of carriers of 2 mutant LCAT alleles, who fre-
quently develop kidney disease,13 the prevalence of hyper-
tension was greater in the carriers group (Table 1). As
expected, carriers displayed marked reductions in HDL-C
(Table 1), contributing to lower plasma total cholesterol
levels than BD controls; there was no difference in LDL
cholesterol (LDL-C) levels between the 2 groups. Carriers
also had a greater fasting triglyceride level and lower apoli-
poprotein (apo)A-I and apoA-II levels than BD controls
(Table 1). An evaluation of the LDL-C/HDL-C ratio, which is
frequently associated with changes in cardiovascular risk,17
showed that this ratio was remarkably greater among carriers
than among BD controls: 3.30 (2.07, 4.88) versus 1.82 (1.43,
2.44) (P0.0001).
Mean carotid IMT values in the 2 study groups are reported
in Table 2. The thickness of all 3 examined carotid segments
was significantly lower in carriers than in BD controls. The
difference in average IMT, which averages all IMT measure-
ments in each individual, was highly statistically significant.
The maximum IMT value, which reflects the presence of
focal atherosclerotic lesions, was also significantly lower in
carriers than in BD controls. After adjustment for age, sex,
BMI, smoking status, hypertension, family history of cardio-
vascular disease, ultrasound device, and total cholesterol,
HDL-C, and triglyceride levels, the difference in both aver-
age IMT and maximum IMT remained statistically significant
Table 1. Demographic, Clinical, and Lipid/Lipoprotein Data in Carriers of LCAT Gene Mutations and BD Controls
Carriers Carriers of 2 Mutant LCAT Alleles Carriers of 1 Mutant LCAT Allele BD Controls P (Carriers vs BD Controls)
n 40 12 28 80
Sex, M/F 25/15 10/2 15/13 50/30   
Age, y 41.717.0 32.45.9 45.718.7 41.516.7   
BMI, kg/m2 24.84.3 23.73.7 25.34.6 23.73.5 0.15
Smoking status, n (%) 0.78
Never 28 (70.0) 7 (58.3) 21 (75.0) 53 (66.0)
Former 7 (17.5) 4 (33.3) 3 (10.7) 13 (16.3)
Current 5 (12.5) 1 (8.3) 4 (14.3) 14 (17.5)
Hypertension, n (%) 9 (22.5) 4 (33.3) 5 (17.9) 4 (5.0) 0.01
Total cholesterol, mg/dL 164.256.5 155.379.0 167.944.9 183.927.7 0.04
LDL-C, mg/dL 102.751.5 99.470.7 104.242.3 107.325.8 0.60
HDL-C, mg/dL 30.117.4 9.14.7 39.112.2 58.412.2 0.0001
ApoA-I, mg/dL 83.334.2 39.58.3 102.121.1 140.622.9 0.0001
ApoA-II, mg/dL 23.911.8 8.24.5 30.76.0 35.15.1 0.0001
Triglycerides, mg/dL 156.5111.3 234.5165.4 123.053.7 95.666.5 0.002
Glucose, mg/dL 90.437.4 77.68.7 95.042.7 88.011.3 0.62
Data are reported as meanSD unless indicated otherwise.
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(Table 2). Two carriers, both heterozygote women, had a
stroke at the age of 68 and 70 years.
Carotid IMT in Carriers of 2 and 1 Mutant
LCAT Alleles
In a second analysis, the effect of the number of copies of
mutant alleles (gene-dose effect) on average IMT and maxi-
mum IMT was investigated by ANCOVA, with the number
of mutant alleles (0, 1, or 2) as independent variable and
testing for trend. The characteristics of the present cohort of
carriers of 2 and 1 mutant alleles (Table 1) were close to those
previously reported for the entire series of identified carri-
ers.13 After adjustment for age, sex, BMI, smoking status,
hypertension, family history of cardiovascular disease, ultra-
sound device, and total cholesterol, HDL-C, and triglyceride
levels, a mutation in the LCAT gene had a significant
gene-dose–dependent effect on all IMT measurements (Table
2 and Figure). The gene-dose model fit the IMT data better
than the dominant model (F10.7 versus 6.8 for average IMT
and F7.8 versus 6.9 for maximum IMT). When adjusted
IMT values in carriers of 2 or 1 mutant LCAT alleles were
compared with those of BD controls (Table 2), a highly
significant difference was found in both average IMT
(P0.0009 and P0.002 for carriers of 2 and 1 mutant
alleles, respectively) and maximum IMT (P0.01 and 0.004
for carriers of 2 and 1 mutant alleles, respectively).
Carotid IMT in FLD and FED
In a third analysis, a comparison was made between subjects
phenotyped as FLD and FED. Differential FLD and FED
diagnosis in carriers of 2 mutant LCAT alleles was based on
biochemical criteria13: 9 of the 12 examined carriers were
classified as FLD and 3 as FED. Because carriers of 1 mutant
LCAT allele cannot be classified as FLD or FED on the basis
of either biochemical or clinical criteria,11 differential genetic
diagnosis was performed by expressing LCAT mutants in
COS-1 cells and measuring LCAT concentration and activity
in the cell medium (Table 3). Twenty-four heterozygotes
carry either a truncated LCAT mutant (n5) or an LCAT
mutant displaying undetectable activity against both recon-
stituted HDL and LDL substrates (n19) and were thus
classified as FLD. Four heterozygotes carry an LCAT mutant
Table 2. IMT of the Common, Bifurcation, and Internal Carotid Artery Segments in Carriers of LCAT Gene Mutations and
BD Controls
Carriers
Carriers of 2 Mutant
LCAT Alleles
Carriers of 1 Mutant
LCAT Allele BD Controls P (Carriers vs BD Controls) P (Trend)*
Unadjusted model
Common carotid, mm 0.55 (0.52–0.59) 0.49 (0.44–0.55) 0.57 (0.54–0.62) 0.59 (0.56–0.61) 0.021 0.009
Bifurcation, mm 0.62 (0.56–0.69) 0.49 (0.41–0.59) 0.68 (0.61–0.77) 0.75 (0.70–0.80) 0.001 0.0001
Internal carotid, mm 0.56 (0.52–0.60) 0.49 (0.42–0.56) 0.59 (0.54–0.65) 0.64 (0.60–0.67) 0.001 0.001
Average IMT, mm 0.58 (0.54–0.62) 0.50 (0.44–0.56) 0.62 (0.57–0.67) 0.65 (0.62–0.68) 0.0003 0.0005
Maximum IMT, mm 0.91 (0.81–1.02) 0.72 (0.59–0.88) 1.00 (0.88–1.14) 1.12 (1.03–1.21) 0.0027 0.0002
Adjusted model
Common carotid, mm 0.55 (0.52–0.58) 0.52 (0.47–0.59) 0.55 (0.52–0.58) 0.59 (0.57–0.61) 0.108 0.04
Bifurcation, mm 0.62 (0.57–0.67) 0.54 (0.45–0.64) 0.63 (0.58–0.68) 0.76 (0.72–0.80) 0.015 0.0001
Internal carotid, mm 0.55 (0.52–0.59) 0.52 (0.45–0.60) 0.56 (0.52–0.59) 0.64 (0.61–0.67) 0.009 0.002
Average IMT, mm 0.58 (0.55–0.61) 0.53 (0.47–0.60) 0.58 (0.55–0.61) 0.66 (0.63–0.68) 0.0011 0.0003
Maximum IMT, mm 0.92 (0.84–1.00) 0.82 (0.68–1.00) 0.93 (0.84–1.01) 1.12 (1.06–1.19) 0.007 0.001
Data are reported as geometric mean and 95% CI. In the adjusted model, IMT values were adjusted for age, sex, BMI, smoking status, hypertension, family history
of cardiovascular disease, ultrasound device, and total cholesterol, HDL-C, and triglyceride levels.
*P for linear trend over the number of mutant alleles.
Figure. Average IMT (Avg-IMT) and maximum IMT (Max-IMT)
values in carriers of 1 (n28) or 2 (n12) mutant LCAT alleles
and in control subjects (n80). IMT measurements were
adjusted for age, sex, BMI, smoking status, hypertension, family
history of cardiovascular disease, ultrasound device, and total
cholesterol, HDL-C, and triglyceride levels. Data are expressed
as geometric mean and 95% CIs. P0.0003 for average IMT
and P0.001 for maximum IMT when tested for trend.
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displaying no activity against reconstituted HDL but detect-
able activity against LDL and were classified as FED. IMT
data from homozygous and heterozygous carriers with the
same phenotype (either FLD or FED) were combined before
analysis (Table 4). Average IMT and maximum IMT were
similar in FLD and FED carriers and remained similar after
adjustment for age, sex, BMI, smoking status, hypertension,
family history of cardiovascular disease, ultrasound device,
and total cholesterol, HDL-C, and triglyceride levels (Table
4). However, this nonsignificant result should be taken with
caution because, given the observed variability, the limited
sample size allowed us to detect as significant (with 0.05)
an estimated difference of 0.19 mm between the 2 groups
with an 80% statistical power.
Discussion
In the present study, we took advantage of the previous
identification of 13 hypoalphalipoproteinemia families carry-
ing different mutations in the LCAT gene13 to investigate the
impact of defective LCAT function on preclinical atheroscle-
rosis, as assessed by measuring carotid IMT. Unexpectedly,
the low HDL-C levels in carriers of LCAT gene mutations do
not result in premature atherosclerosis. Indeed, the inheri-
tance of a mutated LCAT genotype has a remarkable gene-
dose–dependent effect in reducing carotid IMT. Moreover,
there is no difference in carotid IMT between carries of LCAT
gene mutations that cause total or partial LCAT deficiency
(ie, FLD or FED).
Three different data analyses have been performed in the
present study. First, we compared IMT data from carriers of
LCAT gene mutations (1 and 2 mutated alleles together) with
those from a double number of age/sex-matched healthy
controls. On average, carriers had a 0.07 mm smaller average
IMT and a 0.21 mm smaller maximum IMT than controls, a
difference that remained statistically significant after adjust-
ment for a variety of cardiovascular risk factors known to
affect artery wall thickness. Mean average IMT and maxi-
mum IMT in carriers of LCAT gene mutations were 0.22
(95% CI, 0.06 to 0.37) mm and 0.52 (95% CI, 0.14 to
0.90) mm smaller than IMT measurements made by the same
sonographers in 55 slightly older individuals with hypoal-
phalipoproteinemia, after adjustment for age.4 Notably, both
IMT measurements were strikingly similar to those measured
in individuals with hypoalphalipoproteinemia of approxi-
mately the same age carrying the atheroprotective apoA-IMilano
mutation.9 Therefore, LCAT deficiency is another monogenic
disorder of HDL metabolism leading to a paradoxical pheno-
type characterized by moderate to severe HDL deficiency
without enhanced preclinical atherosclerosis.
In a second analysis, all the examined subjects were
subgrouped according to the number of mutant alleles, and a
highly significant gene-dose–dependent effect of the LCAT
genotype on carotid IMT was found. The inheritance of a
single mutant LCAT allele leads to an extent of preclinical
atherosclerosis intermediate between that of carriers of 2 or 0
copies of mutant alleles. A striking LCAT gene-dose–depen-
dent effect on cholesterol esterification and other HDL-
related biomarkers has been found in the same families,13,18
indicating that both the biochemical and the vascular changes
are expressed as codominant traits in families carrying
mutations in the LCAT gene.
The third analysis was aimed at comparing IMT values
from carriers of LCAT gene mutations causing complete or
partial (ie, FLD and FED) enzyme inactivation. On the basis
of genotype, 7 carriers of 2 mutant alleles (all FLD) were
homozygotes for the same mutation, and 5 (2 FLD and 3
FED) carried 2 distinct mutations.13 When mutations were
categorized by site-directed mutagenesis, the 2 compound
Table 3. Concentration and Activity of Missense LCAT
Mutants Expressed in COS-1 Cells
LCAT Mass,
g/mL
LCAT Activity, nmol/(mLh)
Mutant Reconstituted HDL LDL Phenotype
WT 0.280.05 12.71.8 76.210.7
S91P 0.400.14 0 0 FLD
A141T 0.270.08 0 117.3 FED
R147W 0.160.02 0 0 FLD
S181N 0.450.02 0 0 FLD
K218N 0.220.05 0 0 FLD
R244H 0.390.02 0 110.2 FED
T274I 0.270.06 0 0 FLD
V309M 0.320.03 0 0 FLD
L372R 0.160.07 0 0 FLD
Data are reported as meanSD.
Table 4. Demographic, Clinical, Lipid/Lipoprotein, and IMT
Data in FLD and FED Carriers
FLD FED P
N 33 7
Sex, M/F 20/13 5/2 0.69
Age, y 43.017.5 35.614.3 0.30
BMI, kg/m2 24.84.6 25.22.4 0.86
Smoking status, n (%) 0.45
Never 22 (66.7) 6 (85.7)
Former 7 (21.2) 0
Current 4 (12.1) 1 (14.3)
Hypertension, n (%) 8 (24.2) 1 (14.3) 0.71
Total cholesterol, mg/dL 164.152.4 164.678.1 0.98
LDL-C, mg/dL 99.347.6 119.169.0 0.36
HDL-C, mg/dL 31.817.7 22.014.3 0.18
ApoA-I, mg/dL 85.234.8 74.332.4 0.45
ApoA-II, mg/dL 23.711.7 25.113.5 0.76
Triglycerides, mg/dL 164.7119.0 117.453.7 0.32
Glucose, mg/dL 91.339.1 80.38.1 0.63
Average IMT, mm 0.58 (0.53–0.64) 0.56 (0.46–0.69) 0.72
Maximum IMT, mm 0.93 (0.81–1.07) 0.81 (0.60–1.10) 0.42
Adjusted average IMT, mm 0.66 (0.57–0.78) 0.59 (0.54–0.64) 0.15
Adjusted maximum IMT, mm 0.94 (0.75–1.19) 0.97 (0.86–1.09) 0.84
Data are reported as meanSD unless indicated otherwise. IMT data are
expressed as geometric mean (95% CI). In the adjusted model, IMT values
were adjusted for age, sex, BMI, smoking status, hypertension, family history
of cardiovascular disease, ultrasound device, and total cholesterol, HDL-C, and
triglyceride levels.
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heterozygotes with FLD were found to carry 2 different FLD
mutations, whereas the 3 compound heterozygotes with FED
were found to carry 1 FLD and 1 FED mutation. In the latter
cases, the combined effect of the 2 mutations might have
resulted in some kind of intermediate phenotype, whose
clinical features were not easily distinguishable from those of
classic FED. Obviously, any transposition of an in vitro
biochemical property of the mutant (activity against LDL but
not HDL) to the in vivo situation is an oversimplification in
terms of the clinical phenotype found in the carriers. Because
of the small number of carriers, data from homozygotes,
compound heterozygotes, and heterozygotes with the same
phenotype (either FLD or FED) were combined in this
analysis. Both average IMT and maximum IMT were similar
in FLD and FED carriers and remained similar after adjust-
ment for a variety of cardiovascular risk factors. The inves-
tigation of the biochemical phenotype of these same carriers
demonstrated that, despite the different functional defect of
the LCAT enzyme, the lipid/lipoprotein phenotype of FLD
and FED carriers is largely indistinguishable13; here we show
that the same occurs at the vascular level. Altogether, these
findings support the concept that FLD and FED are not 2
distinct syndromes but the same disease at different levels of
LCAT impairment.
LCAT catalyzes the transacylation of the sn-2 fatty acid of
lecithin to the free 3-OH group of cholesterol, generating
cholesteryl ester and lysolecithin,19 and plays a central role in
intravascular HDL metabolism and in reverse cholesterol
transport,10 the process believed to explain HDL-mediated
atheroprotection. A defect in LCAT function is thus expected
to enhance atherosclerosis by interfering with these pro-
cesses. The present data demonstrate exactly the opposite: In
the subjects studied here, a partial or complete dysfunction of
the LCAT enzyme is associated with reduced preclinical
atherosclerosis. This unexpected finding merits some specu-
lation. The inheritance of a defective LCAT enzyme may not
preclude cholesterol removal from the arterial wall and
efficient reverse cholesterol transport. Indeed, sera from these
same carriers of LCAT gene mutations displayed an enhanced
capacity for ABCA1-mediated cell cholesterol efflux than
sera from unaffected family members because of the greater
content of pre--HDL particles.18 Notably, LCAT-deficient
mice display a preserved reverse cholesterol transport in vivo
despite the severe HDL-C reduction, primarily because of the
high plasma content of pre--HDL and enhanced macro-
phage cholesterol removal via ABCA1.20 Moreover, kinetic
studies in humans show that unesterified cholesterol within
HDL may be efficiently delivered to the liver and excreted
into bile without conversion into cholesteryl ester.21 Never-
theless, the preserved reverse cholesterol transport might not by
itself justify the reduced preclinical atherosclerosis observed in
the carriers, which may result from delayed cholesterol deposi-
tion in the arterial wall, as a consequence of a reduced cho-
lesteryl ester content of apoB-containing lipoproteins,22 or a
redistribution of HDL-bound antioxidant enzymes, like
paraoxonase-1, or both to apoB-containing lipoproteins.23
The effect of LCAT on human atherogenesis has been
controversial. Early cross-sectional studies have reported
both decreased24,25 and increased26 LCAT activity in patients
with angiographically proven CAD. No prospective studies
relating baseline LCAT activity/concentration to future car-
diovascular events have been performed yet. Genetic LCAT
deficiency may thus be a valuable model to investigate the
relationship between LCAT and CAD, but the small number
of events in the limited series of affected individuals inves-
tigated thus far and the essentially anecdotal nature of these
reports are of little help in clarifying this issue. Carotid IMT
has been established as a surrogate marker for human
atherosclerosis3 and has been applied to the study of human
atherosclerosis in hypoalphalipoproteinemia patients carrying
mutations in the apoA-I, ABCA1, and GBA genes.8,9,27,28
Notably, despite the common hypoalphalipoproteinemia trait,
carriers of different mutations display carotid IMT values that
are greater than8,27 or close to9,28 those of controls. Three
recent studies evaluated the extent of preclinical atheroscle-
rosis in carriers of LCAT gene mutations by measuring
carotid IMT. In the first study, 2 homozygotes and 7
heterozygotes, aged up to 70 years, from a large Canadian
kindred with FLD have been followed for 25 years, during
which none had suffered any vascular events.29 No control
(unaffected) subjects were included for comparison. Both
homozygotes had a carotid IMT “slightly over the 75th
percentile for their sex and age,”29 which did not progress
over 4 years (1997–2001); they also had normal endothelial
function, as measured by flow-mediated dilation of brachial
artery. The heterozygotes had greater carotid IMT than
homozygotes; 4 of them had a carotid IMT 75th percentile.
On average, the heterozygous carriers had a 0.236 mm greater
total carotid IMT than the expected reference value.29 In the
second study, 9 homozygotes (or compound heterozygotes)
and 47 heterozygotes from 5 Dutch FED families were
investigated; 2 heterozygotes had premature CHD.30 The
homozygotes had greater average carotid IMT than controls,
but the low number of cases and the relatively old age did not
provide adequate power for statistical evaluation; the het-
erozygotes had slightly greater average carotid IMT than
controls (0.032 mm).30 The third study examined a limited
number of American hypoalphalipoproteinemia patients,
some of whom carry mutations in the LCAT gene; mean
carotid IMT values were not different between hypoalphali-
poproteinemia cases and controls.31 These previous findings
are clearly at variance with those found in the present study.
The explanation for this discrepancy is not readily apparent,
although it may be related to a distinctly lower prevalence of
cardiovascular risk factors other than low HDL-C in the
Italian LCAT-deficient families. Indeed, slightly lower mean
plasma LDL-C and BMI values were found in the Italian than
other carriers. Moreover, in the Dutch study, a greater
prevalence of male subjects and smokers among carriers than
controls may have biased the results in favor of enhanced
IMT among LCAT-deficient heterozygotes.30
Some aspects of this study merit caution. The study sample
was relatively small, despite the great effort in recruiting as
many carriers as possible. However, the IMT studies in other
rare genetic HDL disorders mentioned above have examined
cohorts of the same size.9,29,30 A potential limitation in studies
of small cohorts like this one is the referral basis of the
examined subjects. Almost half of the Italian probands were
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identified and referred to us by lipid clinics because of low
HDL-C level, with the others being identified and referred by
departments of nephrology because of impaired renal func-
tion. Both conditions have been independently associated
with enhanced carotid IMT, thus excluding a bias for select-
ing probands carrying LCAT gene mutations associated with
reduced preclinical atherosclerosis and cardiovascular disease
risk. Another possible limitation of this study lies in the lack
of unaffected family members as controls; however, only 6
unaffected relatives, with a sex-age distribution remarkably
different from that of carriers, provided consent to ultrasound
investigation.
In conclusion, the present study shows that genetically
determined low-LCAT activity in Italian families is not
associated with enhanced preclinical atherosclerosis de-
spite low HDL-C levels. This finding challenges the notion
that LCAT is required for effective atheroprotection and
suggests that, despite positive effects on plasma HDL-C
concentration, elevating LCAT expression or activity is
not a promising therapeutic strategy to reduce cardiovas-
cular risk.
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CLINICAL PERSPECTIVE
Population studies clearly demonstrate that a low plasma high-density lipoprotein cholesterol (HDL-C) concentration is a
strong predictor of future coronary heart disease. Genetically determined low HDL-C states, however, may be associated
with a widely variable cardiovascular risk. In the present study, we show that individuals with a defect in cholesterol
esterification, due to mutations in the gene coding for the lecithin:cholesterol acyltransferase enzyme, have low HDL-C
levels but do not present with enhanced preclinical atherosclerosis, as assessed by measuring carotid intima-media
thickness. This finding complements previous observations on the lack of preclinical atherosclerosis and premature
coronary heart disease in other genetic conditions leading to reduced plasma HDL-C levels, like the apolipoprotein A-IMilano
mutation. It illustrates that HDL-C levels per se do not necessarily reflect the atheroprotective potential of HDL-C and
highlights the need for novel tools for cardiovascular risk prediction in individuals with low HDL-C. Moreover, it
challenges the notion that lecithin:cholesterol acyltransferase is required for effective atheroprotection and suggests that,
despite positive effects on plasma HDL-C concentration, elevating lecithin:cholesterol acyltransferase expression or
activity is not a promising therapeutic strategy to reduce cardiovascular risk.
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